CURRENT MEDICATIONS OVERVIEW,,
MEDICATION,GENE(S),PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST
"Citalopram",CYP2C19,Major – significant result that may require altering this medication
"Melatonin",CYP1A2,"Minor – result should be considered as may affect medicationresponse"
"Pantoprazole",CYP2C19,"Minor – result should be considered as may affect medicationresponse"
"Risperidone(component ofRisperidone)",CYP2D6,"Minor – result should be considered as may affect medicationresponse"
"Chlorpromazine",CYP2D6,Usual prescribing considerations apply
MEDICATIONS THAT DO NOT HAVE PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST,,
"buprenorphine hydrochloride / naloxone (Suboxone), buspirone, metformin, zopiclone, lorazepam",,
MEDICATIONS WITH MAJOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Antidepressants -SSRIs",Citalopram,CYP2C19,Reduced / inadequate response,CPIC1
"",Escitalopram,CYP2C19,Reduced / inadequate response,CPIC1
"Antidepressants -tricyclic",Amitriptyline,"CYP2D6CYP2C19",Reduced / inadequate response,CPIC4
MEDICATIONS WITH MAJOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
antidepressants,Clomipramine,"CYP2D6CYP2C19",Reduced / inadequate response,CPIC4
"",Doxepin,"CYP2D6CYP2C19",Reduced / inadequate response,CPIC4
"",Imipramine,"CYP2D6CYP2C19",Reduced / inadequate response,CPIC4
Antifungals - Azoles,Voriconazole,CYP2C19,Reduced / inadequate response,CPIC5
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"ADHD -miscellaneous agents",Atomoxetine,CYP2D6,Adverse effects,-
Antiarrhythmics,Flecainide,CYP2D6,Adverse effects,DPWG3
"",Propafenone,CYP2D6,Adverse effects,DPWG3
Anticoagulants,Acenocoumarol,"VKORC1CYP2C9","Increased acenocoumarolsensitivity",
"",Warfarin,"VKORC1CYP2C9",Increased warfarin sensitivity,FDA6
"Antidepressants -other",Mirtazapine,"CYP2D6CYP1A2",Altered response,-
"",Moclobemide,CYP2C19,Reduced / inadequate response,-
"Antidepressants -serotoninnoradrenalinereuptake inhibitors",Duloxetine,"CYP2D6CYP1A2",Reduced / inadequate response,-
"",Venlafaxine,CYP2D6,Adverse effects,DPWG3
"Antidepressants -SSRIs",Paroxetine,CYP2D6,Adverse effects,CPIC1
"",Sertraline,CYP2C19,Reduced / inadequate response,CPIC1
"Antidepressants -tricyclicantidepressants",Desipramine,CYP2D6,Adverse effects,CPIC4
"",Nortriptyline,CYP2D6,Adverse effects,CPIC4
Antidiabetics,Gliclazide,"CYP2C9CYP2C19",Reduced / inadequate response,-
Antiemetics,Ondansetron,CYP2D6,"Increased therapeutic and/oradverse effects",CPIC7
Antihistamines,Chlorpheniramine,CYP2D6,Adverse effects,-
"",Dexchlorpheniramine,CYP2D6,Adverse effects,-
Antiplatelet drugs,Clopidogrel,CYP2C19,Adverse effects,CPIC8
Antipsychotics,Aripiprazole,CYP2D6,Adverse effects,-
"",Brexpiprazole,CYP2D6,Adverse effects,-
"",Clozapine,CYP1A2,Reduced / inadequate response,-
"",Haloperidol,CYP2D6,Adverse effects,-
"",Olanzapine,CYP1A2,Reduced / inadequate response,-
"",Pimozide,CYP2D6,Adverse effects,
"",Risperidone,CYP2D6,Adverse effects,DPWG3
"",Zuclopenthixol,CYP2D6,Adverse effects,DPWG3
Antitussives,Dextromethorphan,CYP2D6,Altered response,-
Benzodiazepines,Clobazam,CYP2C19,Reduced / inadequate response,-
"",Diazepam,CYP2C19,Reduced / inadequate response,-
Beta blockers,Metoprolol,CYP2D6,Adverse effects,DPWG3
Propranolol,"CYP2D6CYP1A2",Altered response,-,
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
Hypnotics,Melatonin,CYP1A2,Reduced / inadequate response,-
"Immunomodulatorsand antineoplastics",Tamoxifen,CYP2D6,Reduced / inadequate response,CPIC9
Miscellaneous,Cyclophosphamide,CYP2C19,"Increased therapeutic and/oradverse effects",-
"",Eliglustat,CYP2D6,Adverse effects,TGA10
"",Proguanil,CYP2C19,Altered response,-
Neurological drugs,Tetrabenazine,CYP2D6,Adverse effects,FDA11
Opioid Analgesics,Morphine,OPRM1,"Associated with reducedresponse to morphine",-
"Proton pumpinhibitors",Dexlansoprazole,CYP2C19,Reduced / inadequate response,-
Esomeprazole,CYP2C19,Reduced / inadequate response,-,
Lansoprazole,CYP2C19,Reduced / inadequate response,-,
Omeprazole,CYP2C19,Reduced / inadequate response,-,
Pantoprazole,CYP2C19,Reduced / inadequate response,-,
Rabeprazole,CYP2C19,Reduced / inadequate response,-,
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Angiotensin receptorblockers",Irbesartan,CYP2C9,"No altered effect predicted bygenotype",-
"",Losartan,CYP2C9,"No altered effect predicted bygenotype",-
"Anticholinergics(genitourinary)",Darifenacin,CYP2D6,"No altered effect predicted bygenotype",-
"",Fesoterodine,CYP2D6,"No altered effect predicted bygenotype",-
"",Tolterodine,CYP2D6,"No altered effect predicted bygenotype",-
Anticholinesterases,Donepezil,CYP2D6,"No altered effect predicted bygenotype",-
"",Galantamine,CYP2D6,"No altered effect predicted bygenotype",-
"Antidepressants -other",Vortioxetine,CYP2D6,"No altered effect predicted bygenotype",-
"Antidepressants -SSRIs",Fluoxetine,"CYP2D6CYP2C9","No altered effect predicted bygenotype",-
"",Fluvoxamine,"CYP2D6CYP1A2","No altered effect predicted bygenotype",CPIC1
Antidiabetics,Glimepiride,CYP2C9,"No altered effect predicted bygenotype",-
"",Glyburide,CYP2C9,"No altered effect predicted bygenotype",-
Antiemetics,Metoclopramide,CYP2D6,"No altered effect predicted bygenotype",-
Antiepileptics,Phenytoin,CYP2C9,"No altered effect predicted bygenotype",CPIC12
Antihistamines,Promethazine,CYP2D6,Adverse effects,-
Antipsychotics,Chlorpromazine,CYP2D6,"No altered effect predicted bygenotype",-
Quetiapine,CYP3A4,"No altered effect predicted bygenotype",-,
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
Beta blockers,Carvedilol,CYP2D6,"No altered effect predicted bygenotype",-
"",Nebivolol,CYP2D6,"No altered effect predicted bygenotype",-
Calcineurin inhibitors,Tacrolimus,CYP3A5,"No altered effect predicted bygenotype",CPIC13
"Glaucoma - ocularpreparations",Timolol,CYP2D6,"No altered effect predicted bygenotype",-
Miscellaneous,Atazanavir,CYP3A5,"No altered effect predicted bygenotype",-
"",Naltrexone,OPRM1,"No altered effect predicted bygenotype for naltrexone",
NSAIDs,Celecoxib,CYP2C9,"No altered effect predicted bygenotype",-
"",Diclofenac,CYP2C9,"No altered effect predicted bygenotype",-
"",Flurbiprofen,CYP2C9,"No altered effect predicted bygenotype",-
"",Ibuprofen,CYP2C9,"No altered effect predicted bygenotype",-
"",Indomethacin,CYP2C9,"No altered effect predicted bygenotype",-
"",Mefenamic Acid,CYP2C9,"No altered effect predicted bygenotype",-
"",Meloxicam,CYP2C9,"No altered effect predicted bygenotype",-
"",Piroxicam,CYP2C9,"No altered effect predicted bygenotype",-
Opioid Analgesics,Codeine,"CYP2D6OPRM1","Associated with reducedsensitivity to codeine",CPIC14
"",Hydrocodone,CYP2D6,"No altered effect predicted bygenotype",
"",Oxycodone,CYP2D6,"No altered effect predicted bygenotype",DPWG3
"",Tramadol,CYP2D6,"No altered effect predicted bygenotype",DPWG3
Psychostimulants,Dextroamphetamine,CYP2D6,"No altered effect predicted bygenotype",-
"",Lisdexamfetamine,CYP2D6,"No altered effect predicted bygenotype",-
Statins,Atorvastatin,"SLCO1B1CYP3A4","No altered effect predicted bygenotype",-
Fluvastatin,"SLCO1B1CYP2C9","No altered effect predicted bygenotype",-,
Pravastatin,SLCO1B1,"No altered effect predicted bygenotype",-,
Rosuvastatin,SLCO1B1,"No altered effect predicted bygenotype",-,
Simvastatin,"SLCO1B1CYP3A4","No altered effect predicted bygenotype",CPIC15,
